Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares.
Where this comes from
- Record sourced from PubMed, PMID 40591420.
- Also identified by DOI 10.1172/JCI188530 and PMC identifier 12404765.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
People with generalized pustular psoriasis experience underlying skin inflammation, even in the absence of flares. Spesolimab treatment helps control the inflammation and prevent future flares.
Medical subject headings
- Psoriasis
- Receptors, Interleukin
- Antibodies, Monoclonal, Humanized